[Clinico-quatitative evaluation of the action of Ciba 34.647-Ba on spasticity].
Using the clinical quantification of the neurologic symptomatology the authors made observations and avaliated the action of Ciba 34.647-Ba, a GABA derivative, in 12 patients suffering from spasticity and motor incapacity due to spinal cord lesions. The results are reported emphasizing the effects of the drug on the main components of spasticity (hypertonus, hyperactivity of the deep reflexes, clonus and automatisms). Some theories explaining the mechanism of action of the drug are mentioned. References are made about doses, duration of action, tolerance and side-effects.
D000328:Adult; D000368:Aged; D000613:Aminobutyrates / Q000627:therapeutic use*; D001418:Baclofen / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013035:Spasm / Q000188:drug therapy* / Q000209:etiology; D013119:Spinal Cord Injuries / Q000150:complications / Q000188:drug therapy; D013120:Spinal Cord Neoplasms / Q000150:complications / Q000188:drug therapy
D000613:Aminobutyrates; D001418:Baclofen
Avaliação clinico-quantitativa da ação do Ciba 34.647-Ba sobre a espasticidade.